Alzheon Fully Enrolls Phase 2 Biomarkers Study of Oral ALZ-801

Alzheon Fully Enrolls Phase 2 Biomarkers Study of Oral ALZ-801

298500

Alzheon Fully Enrolls Phase 2 Biomarkers Study of Oral ALZ-801

Patient enrollment is now complete for Alzheon’s Phase 2 study evaluating the effects of ALZ-801 on disease-related biomarkers in people with early Alzheimer’s. All of the participants — double the original target number — have a specific genetic variant associated with an increased risk of disease progression. Alzheon said it expects the first interim data from the trial to be released in 2022. The enrollment target of 80 participants was expanded from its original number…

You must be logged in to read/download the full post.